{"id":"W2060432974","doi":"10.1038/pcan.2013.2","title":"Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Medicine; Placebo; Prostate cancer; Hazard ratio; Internal medicine; Interim analysis; Adverse effect; Randomized controlled trial; Confidence interval; Oncology; Cancer; Urology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003722835,0.000511721,0.001944255,0.0002908779,0.000120124,0.0001035953,0.0001000795,0.00004120904,0.0002351959],"category_scores_gemma":[0.0001828719,0.0003311678,0.0001275922,0.0004746034,0.0002921844,0.0004292695,0.00004185556,0.0002057701,0.000004768795],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000135319,"about_ca_system_score_gemma":0.0005497735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005489714,"about_ca_topic_score_gemma":0.0004805505,"domain_scores_codex":[0.9967042,0.000273635,0.001127544,0.000609041,0.0006916994,0.0005939046],"domain_scores_gemma":[0.9978594,0.0003876656,0.0005392818,0.00032463,0.0004809835,0.0004080422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7115431,0.006793232,0.2425043,0.001370438,0.0009035359,0.00009265808,0.007105691,0.0002620493,0.0004238132,0.000006136593,0.0002553421,0.02873969],"study_design_scores_gemma":[0.9068007,0.004990218,0.07918935,0.000888001,0.002121819,0.000002200725,0.003086196,0.0021351,0.0001740185,0.0001531522,0.0000143581,0.0004448715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758081,0.001833737,0.000009884265,0.0001921771,0.0001137331,0.0214342,0.000480209,0.00004116951,0.00008682497],"genre_scores_gemma":[0.9881296,0.0005198399,0.0001946559,0.0002034918,0.00003335761,0.01007427,0.0001329555,0.00006513086,0.0006467475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1952576,"threshold_uncertainty_score":0.9999141,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008647926792209042,"score_gpt":0.2850561213410108,"score_spread":0.2764081945488018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}